Momentum Stock in Focus (ATR A Momentum Oscillator) ATR Alerts: Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) with the stream of 13.51% in the last hour of trading session.

Tonix Pharmaceuticals Holding Corp. (TNXP) shares jumped 13.51% to close at $1.05. About 43,865,383 million shares traded hands on 16.77M trades for the day, compared with an average daily volume of 16.77M shares out of a total float of 156.43M. After opening the trading day at $1.04, shares of Tonix Pharmaceuticals Holding Corp. stayed within a range of $1.00 to $1.15.

With today’s gains, Tonix Pharmaceuticals Holding Corp. now has a market cap of $136.22M. Shares of Tonix Pharmaceuticals Holding Corp. have been trading within a range of $0.39 and $2.46 over the last year, and it had a 50-day SMA of $66.23% and a 200-day SMA of $38.30%.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) portfolio comprises small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company’s lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300, a second live replicating vaccine candidate for the prevention of COVID-19 that employs bovin parainfluenza virus as the vector. In addition, the company’s lead CNS candidate is TNX-102 SL, which is in Phase 3 development for fibromyalgia, as well as in Phase 2 studies for agitation in Alzheimer’s disease and alcohol use disorder. Further, its products include TNX-1300, which is in Phase 2 development for the treatment of life-threatening cocaine intoxication; TNX-601 CR (tianeptine oxalate controlled-release tablets) that is in Phase 1 development for depression; and TNX-1900, an intranasal oxytocin as a non-addictive treatment for migraine and cranio-facial pain. Additionally, its preclinical pipeline includes TNX-1600, a triple reuptake inhibitor for posttraumatic stress disorder; TNX-1500, a monoclonal antibody to prevent and treat organ transplant rejection and autoimmune conditions; and TNX 1700, a recombinant modified form of Trefoil Family Factor 2 to treat gastric and pancreatic cancers. It has a research collaboration agreement with Massachusetts General Hospital to develop TNX-1500. The company was founded in 2007 and is based in New York, New York.

The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E ratio. Last traded has a PEG ratio of 0 where as its P/E ratio was 0. The overall volume in the last trading session was 43,865,383 shares.

Important Results:

Tonix Pharmaceuticals Holding Corp. has P/S value of 0 while its P/B esteem remains at 1.89. Likewise, the company has Return on Assets of -106.20%, Return on Equity of -118.20% and Return on Investment of 0. The company demonstrates Gross Margin and Operating Margin of 0 and 0 respectively.

TNXP’s price to sales ratio for trailing twelve months was 0 and price to book ratio for most recent quarter was 1.89, whereas price to cash per share for the most recent quarter was 2.45. The Company’s price to free cash flow for trailing twelve months was recorded as 0.

Historical Performances to Consider:

The Stock’s performances for Monthly, weekly, half-yearly, quarterly & year-to-date are mentioned below:-

On a Monthly basis the stock was 50.41%. On a weekly basis, the stock remained 12.72%. The half-yearly performance for the stock has 63.66%, while the quarterly performance was 21.71%. Looking further out we can see that the stock has moved 37.04% over the year to date. Other technical indicators are worth considering in assessing the prospects for EQT. RSI for instance was stand at 77.66.

Jake Charles

About Jake Charles

This is Jake Charles, a Senior News Writer for “Stocks Equity”. I covers “Active Stocks” sector and writes about trending Active Hot companies from an exclusive and “out of the box” perspective. I worked independently as a self motivator and with the financial institute as financial adviser to invest in the Active sector for over 9 years in the developing countries by introducing new phases and ways to improve in this sector. I like to travel all over the globe to get new experience and provide by best services to the companies. As an advisor I like to work with new people to share and explore new ideas keeping in view minimizing the operating cost and giving the best final product through new technology and minimizing the time of development.

View all posts by Jake Charles →

Leave a Reply

Your email address will not be published. Required fields are marked *